Neurolief Reveals Data on Wearable Digital Therapeutic for Migraine Treatment and Prevention

Relivion MG is a wearable digital therapeutic intended to treat and prevent migraines while also reducing the need for other drug therapies. Neurolief, the company responsible for the device, unveiled data regarding the device at the 65th Annual Scientific Meeting hosted by the American Headache Society, which was held from June 15-18, 2023 in Austin, Texas.

According to Neurolief, the device’s technology applies electrical impulses to six major nerve branches associated with migraines. The device is an external wearable and uses a trigeminal neurostimulation system.

Sixteen subjects participated in the study, each of whom had chronic migraines (or reported a high frequency of migraine occurrences). The results showed that the mean average of days the users reported suffering from migraines reduced from over 17 days a month to just four.

In a press release, Roni Sharon, a neurologist and headache specialist, described the real-world data as “very promising.”

"The remarkable results achieved in this subset of more difficult to treat patient population underscore the immense potential of Relivion's innovative technology in helping millions of people living with migraine,” Sharon said.